Immunobiology of Photodynamic Therapy in Lung Cancer Patients
- To test the hypothesis that the immune response in non-small cell lung cancer patients
treated with photodynamic therapy (PDT) is T cell mediated.
- To test the hypothesis that PDT potentially affects survival rates in these patients.
- To test the hypothesis that T lymphocytes mediate an immune response that affects
survival in PDT treated patients.
OUTLINE: Patients deemed suitable for photodynamic therapy (PDT) are offered PDT. Patients
are divided into 2 groups according to whether or not they receive PDT. All patients are
referred to radiation and medical oncology for standard of care adjuvant therapy (beginning
after completion of this study).
- Group 1 (PDT): Patients receive porfimer sodium IV over 3-5 minutes and undergo
irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day
- Group 2 (non-PDT): Patients undergo a baseline bronchoscopy and a repeat bronchoscopy
at 4 weeks.
Blood sample, bronchoalveolar lavage fluid, and tumor tissue are collected after each
treatment (group 1) or at time of each bronchoscopy (group 2) and assayed for the presence
of lymphocyte phenotypes Th1, Th2, Treg, and Th17. After completion of study therapy,
patients are followed at 1 month after PDT and then every 3 months for 3 years.
PROJECTED ACCRUAL: A total of 236 patients (177 undergoing photodynamic therapy [PDT] and 59
not undergoing PDT) will be accrued for this study.
Allocation: Non-Randomized, Primary Purpose: Treatment
T cell mediated immune response measured by assays of tumor tissue, bronchoalveolar fluid, and plasma
Susan Moffatt-Bruce, MD, PhD
Ohio State University Comprehensive Cancer Center
|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center||Columbus, Ohio 43210-1240|